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Preprocedural hemoglobin predicts outcome in
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Suresh B. Babu, FRCP, FRCR, Birmingham, United Kingdom
Background: Anemia is a risk factor for adverse outcome in patients with symptomatic cardiovascular disease. This study
assessed the association of preprocedural hemoglobin with adverse outcome in patients with advanced peripheral vascular
disease (PVD) undergoing percutaneous transluminal angioplasty (PTA).
Methods: Consecutive first-time procedures for patients with Rutherford category 4 or 5 PVD who underwent successful
nonemergency PTA were analyzed in a retrospective cohort study. Cardiovascular risk factors, preprocedural hemoglo-
bin, and angiographic data were recorded. Preprocedural (<24 hours) hemoglobin was divided into tertiles (first tertile:
10.5  0.7 g/dL; second tertile: 12.0  0.4 g/dL; third tertile: 13.9  0.9 g/dL). Study end points were a composite
of adverse peripheral vascular events consisting of target lesion revascularization (repeat PTA or vascular bypass
operation), limb amputation, or death. Cox regression analysis was used to identify independent predictors of adverse
peripheral vascular outcome.
Results: A total of 101 patients (mean age, 76 10 years) were studied, of which 54 (53%) were men, and 62 (65%) were
anemic. We observed 42 events during a median of 14 months (interquartile range, 4-26 months follow-up). Cox
regression analysis found preprocedural hemoglobin in the first tertile vs third tertile (odds ratio, 4.17; 95% confidence
interval, 1.56-11.16, P  .004), diabetes, renal failure, Rutherford category 5, and tibial vessels runoff score were
independent predictors of adverse peripheral vascular outcome.
Conclusions: Anemia is a common comorbid condition in patients with advanced PVD. Preprocedural hemoglobin could
be used in clinical practice to risk stratify patients with advanced PVD who are being considered for PTA. Correction of
anemia before PTA in patients with Rutherford category 4 and 5 PVD may improve long-term outcome. Further
investigation is needed regarding the optimization of preprocedural hemoglobin. (J Vasc Surg 2009;50:317-21.)Atherosclerosis impairs tissue perfusion and reduces the
delivery of oxygen to metabolically active tissue. Anemia
can further affect oxygen delivery, such that chronic anemia
in heart failure patients has consistently been associated
with a significantly increased risk of death.1-3 Sarnal et al4
demonstrated that in patients with a history of coronary
artery disease (CAD), evidence of anemia was associated
with an increased risk of long-term adverse cardiovascular
outcome. For those patients undergoing percutaneous cor-
onary intervention for symptomatic CAD, preprocedural
anemia increases the risk of both in-hospital and long-term
mortality.5-7 Similarly, anemia in patients undergoing cor-
onary artery bypass grafting is associated with higher in-
hospital mortality.8 Given a shared pathophysiology be-
tween peripheral vascular disease (PVD) and CAD, anemia
is also associated with an increased risk of short-term and
long-term mortality in patients undergoing elective open
vascular surgery for PVD.9
The adverse effect of anemia on long-term outcome
depends on its severity and the presence of comorbidi-
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doi:10.1016/j.jvs.2009.03.041ties.9,10 In the case of mild to moderate anemia, oxygen
delivery is maintained through increased tissue oxygen
extraction.11 In symptomatic PVD, however, an imbalance
exists between oxygen demand and delivery that may be
further compromised by even mild anemia. To the best of
our knowledge, there are no data in the literature address-
ing the prognostic effect of mild anemia in PVD patients
undergoing percutaneous transluminal angioplasty (PTA).
The aim of our study was to determine the effect of prepro-
cedural hemoglobin concentrations on long-term adverse
peripheral vascular outcome in patients with advanced PVD
undergoing PTA.
METHODS
This retrospective cohort study included consecutive
patients with Rutherford12 category 4 or 5 PVD who
underwent successful first-time nonemergency PTA within
a large district general hospital between 2002 and 2004.
The diagnosis of PVD was assigned by means of clinical
evaluation or duplex ultrasound imaging and was con-
firmed by lower limb angiography. The study excluded
patients with a history of surgical lower limb amputation as
a consequence of PVD or previous surgical or endovascular
lower limb revascularization.
Baseline clinical characteristics were defined by patient
self-reporting. Data was collected on age, gender, history of
diabetes mellitus, hypertension, smoking, angina, myocar-
dial infarction, stroke, heart failure, and renal impairment
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hours) hemoglobin concentration in g/dL was divided
into first tertile, 10.5  0.7; second tertile, 12.0  0.4, or
third tertile, 13.9  0.9. Anemia was defined according to
the criteria of the World Health Organization (12.0
g/dL in women and 13.0 g/dL in men).13
A standardized protocol was used for peripheral an-
giography and PTA.14 Before PTA, patients received 3000
IU of intravenous heparin. All interventions were per-
formed by experienced interventional radiologists, and the
PTA technique used was at the discretion of the treating
interventional radiologists. Primary technical success was
defined as a residual stenosis of 50% at the dilated seg-
ment.14 The most severe lesion treated, as determined by
the length and degree of stenosis, was identified as the
index lesion for the procedure and had follow-up for repeat
intervention.
The arterial distributions reported represent the loca-
tion of the index lesion. Lesions were categorized as involv-
ing the superficial femoral artery, common femoral artery,
or popliteal artery, and also according to the TransAtlantic
Inter-Society Consensus (TASC) classification of arterial
lesions.15 Angiographic documentation of preprocedural
tibial runoff vessels was available for all patients. Each of the
three tibial vessels were assigned a run-off score according
to the extent of luminal disease: 0 (50% stenosis), 1
(50%-99% stenosis) or 2 (occluded); and the sum of this
formed the total runoff score (range, 0-6).16 Patients were
stratified into two groups of tibial vessels runoff score: 0 to
2 vs 3 to 6.
During the study period, all patients received life-long
aspirin alternatively or clopidogrel if aspirin was contrain-
dicated. Patients were routinely followed up in the outpa-
tient clinic every 6 months for clinical evaluation of symp-
Table I. Baseline clinical characteristics according to
clinical outcome
Variablesa Overall No event
Adverse
event P
Patients, No. 101 59 42
Age, y 76  10 77  10 75  11 .41
Male gender 54 (53) 25 (42) 29 (69) .01
Diabetes 55 (54) 25 (42) 30 (71) .01
Hypertension 69 (68) 40 (68) 29 (69) .99
Smoker 27 (27) 14 (24) 13 (31) .50
Angina 27 (27) 13 (22) 14 (33) .26
Myocardial infarction 12 (12) 2 (3) 10 (24) .003
Stroke 15 (15) 10 (17) 5 (12) .58
Heart failure 17 (17) 5 (8) 12 (29) .01
Renal impairment 15 (15) 4 (7) 11 (26) .01
Serum creatinine,
mmol/L 111  82 97  37 129  116 .04
Rutherford category 5 69 (68) 35 (59) 34 (81) .03
Angiographic data
Tibial run-off
score 2 60 (59) 26 (44) 34 (81) .001
aCategoric variables are expressed as number (%); continuous variables are
expressed as mean  standard deviation.toms. The study end points included the occurrence ofadverse peripheral vascular events, including target lesion
revascularization (repeat PTA or vascular bypass opera-
tion), surgical limb amputation, or death. After a study end
point was reached patients were no longer monitored for
the occurrence of further study end points.
Statistical analysis. Categoric variables are expressed
as frequencies and percentages, and differences between
groups were assessed using the Pearson 2 or the two-tailed
Fisher exact test. Continuous variables are expressed as
mean standard deviation, and those with a normal distri-
bution were analyzed using a Student t test. Odds ratios
(OR) are reported with a 95% confidence interval (CI). Cox
regression analysis was used to identify independent predic-
tors of adverse peripheral vascular outcome. Kaplan-Meier
survival analysis was used to compare differences in event
rates between tertiles of preprocedural hemoglobin levels
using the log-rank test. Statistical analysis was completed
using SPSS 14.0 software (SPSS Inc, Chicago, Ill). For
analyses, a value of P  .05 was considered statistically
significant.
RESULTS
We studied 101 consecutive patients (53% men) who
were admitted with advanced PVD undergoing nonemer-
gency PTA.Of these, 32 were in Rutherford category 4 and
69 were at category 5. The mean patient age was 76  10
years, 54% were diabetic, 68% were hypertensive, and 27%
were smokers (Table I). Balloon angioplasty was to the
superficial femoral artery in 12 patients, common femoral
artery in 16, popliteal artery in 26, or tibial artery in 47.
Preprocedural femoral-popliteal lesions were classified ac-
cording to TASC criteria and included type A in 33, type B
in 35, type C in 22, and type D in 11. The preprocedural
tibial vessels runoff scores were 0 in 10 patients, 1 in 15, 2
in 16, 3 in 11, 4 in 29, 5 in 9, and 6 in 11. The grouped
tibial vessels runoff scores were 0 to 2 in 41 patients and 3
to 6 in 60. Of the total study population, 62 patients (65%)
were anemic.
There were no in-hospital events. During the median
follow-up of 14 months (interquartile range, 4-26
months), 42 adverse peripheral vascular events occurred,
with 11 repeat PTAs, 9 vascular bypass operations, 9 below
or above knee amputations, and 13 deaths. All of the
revascularization procedures (repeat PTA or vascular by-
pass operation) treated restenosis at the site of the index
lesion. Seven deaths were due to cardiovascular causes, four
resulted from malignancy, and two were due to sepsis.
A significant association was documented between pre-
procedural hemoglobin and both the unadjusted risk of mor-
tality and adverse peripheral vascular outcome (Table II). The
unadjusted OR for adverse peripheral vascular outcome, rela-
tive to the third tertile preprocedural hemoglobin level was
1.96 (95% CI, 0.68-5.67; P .21) for the second tertile and
3.18 (95% CI, 1.12-9.04; P .03) for the first tertile.
Cox regression analysis for predictors of adverse periph-
eral vascular outcome was performed adjusting for age, sex,
diabetesmellitus, hypertension, history of smoking, angina,
myocardial infarction, stroke, heart failure, renal impair-
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2, and tertiles of hemoglobin concentration (Table III).
In addition to diabetes mellitus, renal failure, Rutherford
category 5, and poor tibial runoff, preprocedural hemoglo-
bin in the first tertile (OR, 4.17; 95% CI, 1.56-11.16; P 
.004) and second tertile (OR, 2.99; 95% CI, 1.14-7.53;
P  .03) were independently associated with adverse pe-
ripheral vascular outcome. The Figure demonstrates the
increased risk in limb amputation or target lesion revascu-
larization for patients with a preprocedular hemoglobin
concentration in the first tertile (log-rank test, P  .03).
Cox regression analysis also showed that first vs. third tertile
of preprocedular haemoglobin was an independent predic-
tor of limb amputation or target lesion revascularization
(OR, 5.07; 95% CI, 1.32-19.51; P .01; Table IV) during
the study period.
DISCUSSION
Patients with advanced PVD have a high prevalence of
anemia that is markedly greater than expected for an elderly
population.17,18 Mild to moderate anemia was associated
with an increased risk of mortality and was an independent
predictor of adverse peripheral vascular outcome after PTA
in patients with Rutherford category 4 or 5 PVD. Proce-
dural hemoglobin in the first tertile was associated with a
greater than fourfold increase in risk of adverse peripheral
vascular outcome. Furthermore, preprocedural hemoglo-
bin in the first and second tertiles had a greater predictive
power of adverse outcome than a history of diabetes. In
Table II. Adverse peripheral vascular outcome according




Death 7 (23) 4 (14) 2 (6) .04
Adverse peripheral vascular
outcome 18 (60) 14 (48) 10 (29) .03
Table III. Cox regression analysis for predictors of




Rutherford category 5 4.08 (1.44-11.54) .008
Diabetes 2.95 (1.29-6.75) .01
Renal Failure 3.11 (1.32-7.33) .009
Preprocedural hemoglobin level
1st vs 3rd tertile 4.17 (1.56-11.16) .004
2nd vs 3rd tertile 2.99 (1.14-7.53) .03
Tibial run-off score 2 7.98 (2.91-21.87) .0001
CI, Confidence interval; OR, odds ratio.
aVariables included in the model: sex, diabetes mellitus, prior myocardial
infarction, heart failure, renal failure, Rutherford category, tibial lesion, tibial
run-off score 2, serum creatinine, preprocedural hemoglobin tertiles.addition to anemia, tibial vessels runoff score 2 wasassociated with almost an eightfold increased risk of adverse
outcome.
Previous studies have shown procedural anemia to be
independently associated with risk of mortality in pa-
tients undergoing percutaneous coronary intervention
or coronary artery bypass grafting for symptomatic
CAD.5-7 In this study, preprocedural hemoglobin con-
centration was also an independent predictor of in-
creased risk of limb amputation or target lesion revascu-
larization. This may suggest a role for anemia in the
pathophysiology of restenosis following PTA.
Anemia of chronic disease is associated with a low
concentration of serum iron. Ferrous iron has been shown
to inhibit vascular smooth muscle cell proliferation, which
is a critical process in restenosis.19 During the study period,
the use of stents was not routine and this could also have
contributed to an increased risk of restenosis. In the pres-
ence of impaired tissue perfusion after restenosis, decreased
Fig. Kaplan-Meier curves for the cumulative probability of limb
amputation or target lesion revascularization (TLR) by tertiles of
preprocedural hemoglobin levels.
Table IV. Cox regression analysis for predictors of limb




Male gender 2.94 (2.07-8.08) .03
Preprocedural hemoglobin
(1st vs 3rd tertile) 5.07 (1.32-19.51) .01
Tibial run-off score 2 5.13 (1.54-17.11) .008
CI, Confidence interval; OR, odds ratio.
aVariables included in the model: sex, diabetes mellitus, prior myocardial
infarction, heart failure, renal failure, Rutherford category, tibial lesion, tibial
run-off score 2, serum creatinine, and preprocedural hemoglobin tertiles.oxygen delivery results in continuing tissue ischemia and
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to nearly a fifth of our patients requiring definitive surgical
treatment in the form of vascular bypass operation or
surgical amputation. Anemia is also associated with poor
nutritional status, which may be implicated in an increased
mortality risk of adverse outcome.20
Correcting hemoglobin concentration 10 g/dL in
elderly patients with advanced atherosclerotic disease has
been associated with a reduction in mortality.21 A small
randomized controlled trial demonstrated a reduction in
short-term mortality for heart failure patients with only
mild anemia (hemoglobin between 10 and 11.5 g/dL)
after receiving subcutaneous erythropoietin and intrave-
nous iron.22 We found that patients with advanced PVD
have a high prevalence of anemia, which is also associated
with a significantly increased risk of mortality and adverse
peripheral vascular outcome. For most patients in the first
tertile, preprocedural hemoglobin was higher than the sug-
gested transfusion threshold of 10 g/dL for patients with
symptomatic cardiovascular disease.23,24 This highlights
the importance of investigating in this subset of PVD
patients whether a higher threshold for correction of ane-
mia could improve on long-term outcome.
Because this was an observational study, we were un-
able to adjust for unmeasured potential confounding vari-
ables. A single preprocedural hemoglobin concentration
was recorded, and so it was not possible to account for the
effect of procedural related blood loss, which may com-
pound the effect of low preprocedural hemoglobin. The
duration of anemia was also unknown.
The use of blood transfusions was not recorded; how-
ever, preprocedural hemoglobin for most patients in the
first tertile was higher than the transfusion threshold of 10
g/dL suggested for patients with symptomatic cardiovas-
cular disease.
We were not able to report ankle-brachial pressure
indices for patients at follow-up because this was not rou-
tinely documented in patient notes. Stent use was not
routine during the study period, which could have contrib-
uted to an increased risk of restenosis.
This study is based on actual clinical practice, and so
patients did not have routine follow-up with peripheral
angiography. The decision for repeat angiography after the
index procedure was determined by recurrence or worsen-
ing of clinical symptoms. Therefore, it was not possible to
report on patency rates for the index lesion.
CONCLUSIONS
Anemia is a common comorbid condition in patients
with advanced PVD. Preprocedural hemoglobin was asso-
ciated with an increased risk of mortality and was an inde-
pendent predictor of long-term adverse peripheral vascular
outcome in patients with advanced PVD undergoing non-
emergency PTA. This simple and widely available test could
be routinely used within clinical practice to risk stratify
patients with advanced PVD who are undergoing PTA.
Further investigation is needed to determine whether cor-recting mild preprocedural anemia could improve clinical
outcome in patients with advanced PVD.
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